TCD-10023

TCD-10023 is a **sirolimus-eluting coronary stent** (marketed as Ultimaster) developed to treat coronary artery disease, including small and complex vessels[5][1]. It consists of a thin cobalt-chromium stent coated with sirolimus and an abluminal biodegradable polymer that fully resorbs within ~3 months[1], after which only a bare metal stent remains. Sirolimus is an immunosuppressive and antiproliferative drug that inhibits the mTOR signaling pathway, thus suppressing neointimal hyperplasia and restenosis following stent implantation[5]. Optical imaging and pharmacokinetic studies show nearly undetectable systemic sirolimus after 28 days, indicating a favorable safety profile with minimal drug toxicity[4]. Large clinical trials established strong efficacy and safety for TCD-10023/Ultimaster, including in high-risk and complex patient groups[2][3], with a very low rate of stent strut malapposition and excellent vascular healing[1][4]. The device allows exploration of shortened dual antiplatelet therapy (DAPT), potentially reducing bleeding risks post-PCI[1][2]. Indications include multivessel and bifurcation lesions in patients with coronary artery disease[2][5].

Brand names

Ultimaster

Other names

Sirolimus-eluting coronary stentRapamycin-eluting coronary stent